Your browser doesn't support javascript.
loading
Transversal sero-epidemiological study of Bordetella pertussis in Tehran, Iran.
Noel, Gaelle; Badmasti, Farzad; Nikbin, Vajihe S; Zahraei, Seyed M; Madec, Yoann; Tavel, David; Aït-Ahmed, Mohand; Guiso, Nicole; Shahcheraghi, Fereshteh; Taieb, Fabien.
Afiliación
  • Noel G; Institut Pasteur, Center for Translational Research, Paris, France.
  • Badmasti F; Department of Bacteriology, Pertussis Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.
  • Nikbin VS; Department of Bacteriology, Pertussis Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.
  • Zahraei SM; Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran.
  • Madec Y; Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.
  • Tavel D; Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.
  • Aït-Ahmed M; Institut Pasteur, Centre for Translational Science, Clinical Coordination, Paris, France.
  • Guiso N; Institut Pasteur, Center for Translational Research, Paris, France.
  • Shahcheraghi F; Department of Bacteriology, Pertussis Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.
  • Taieb F; Institut Pasteur, Center for Translational Research, Paris, France.
PLoS One ; 15(9): e0238398, 2020.
Article en En | MEDLINE | ID: mdl-32870922
ABSTRACT

OBJECTIVES:

Pertussis remains endemic despite high vaccine coverage in infants and toddlers. Pertussis vaccines confer protection but immunity wanes overtime and boosters are needed in a lifetime. Iran, eligible for the Expanded Program on Immunization that includes the primary immunization, implemented two additional booster doses using a whole-cell vaccine (wPV) at 18 months-old and about 6 years-old. Duration of protection induced by the wPVs currently in use and their impact as pre-school booster are not well documented. This study aimed at assessing vaccination compliance and at estimating the duration of protection conferred by vaccination with wPV in children aged < 15 years in Tehran, Iran.

METHODS:

Detailed information on vaccination history and capillary blood samples were obtained from 1047 children aged 3-15 years who completed the 3 doses-primary pertussis immunization, in Tehran. Anti-pertussis toxin IgG levels were quantified by ELISA.

RESULTS:

Compliance was very high with 93.3% of children who received the three primary and 1st booster doses in a timely manner. Timeliness of the 2nd booster was lower (63.3%). Rate of seropositive samples continuously and significantly increased from 1-2 to 5-6 years after 1st booster attaining 30.4% of children exhibiting serological sign of recent contact with B. pertussis. Second booster dating back 1 or 2 years was associated with high antibody titers, which significantly decreased within 3 years from injection. Among children who received 2nd booster injection more than 2 years before serum analysis, seroprevalence of pertussis infection was 8.4% and seropositivity rate was higher from the 10 years-old group.

CONCLUSION:

Seropositivity in children aged 6-7 years with no 2nd booster supports the need for a vaccination at that age. Adolescent booster may also be considered.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tos Ferina Límite: Adolescent / Child / Child, preschool / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tos Ferina Límite: Adolescent / Child / Child, preschool / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Francia